In HCC, approximately 5%–10% of patients have abnormal activation of the PI3K/AKT/mTOR pathway, and inhibiting this pathway can significantly inhibit HCC cell proliferation and invasion [28]. Here, AKT1 is linked to hepatocellular carcinoma.